Articles from Kailera Therapeutics, Inc.

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

WALTHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced positive topline data from two additional Phase 3 clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535 (also known as KAI-7535) conducted by Hengrui Pharma: the Phase 3 HARBOR-1 trial (NCT06904105) in adults living with obesity/overweight in China and the Phase 3 OUTSTAND-2 trial (NCT06589765) in adults with type 2 diabetes (T2D) in China.

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the first quarter ended March 31, 2026, and provided a summary of recent business highlights.

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share. All of the shares of common stock were offered by Kailera. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $718.8 million. Kailera’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “KLRA.”

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Kailera, are expected to be $625.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. Kailera’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “KLRA” on April 17, 2026. The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions. In addition, Kailera has granted the underwriters a 30-day option to purchase up to an additional 5,859,375 shares of common stock at the initial public offering price less underwriting discounts and commissions.

– Developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions –